Amgen discontinued AMG 329 (adeczibart) for Sjögren's syndrome after it failed an interim futility analysis in a phase 2 trial.
Amgen terminated four phase 1b/phase 2 trials of AMG 193 (anvumetostat), a PRMT5 inhibitor, for lung cancer, solid tumors, pancreatic cancer, and thoracic cancers due to insufficient efficacy.
The discontinuations involved terminating five clinical trials total.
Despite dropping AMG 329, Amgen continues development of dazodalibep, a CD40 ligand blocker, which is in phase 3 trials for Sjögren's and showed positive phase 2 results.
AMG 732 (formerly HZN-280) remains the only investigational asset from Amgen's Horizon acquisition, in phase 2 for thyroid eye disease.